News for Tiziana Life Sciences Ltd Stock (TLSA)

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

GlobeNewsWire • 11/02/22

Tiziana Life Sciences starts enrollment of first patient cohort in program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients

Proactive Investors • 10/26/22

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

GlobeNewsWire • 10/26/22

Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference

GlobeNewsWire • 10/19/22

Tiziana Life Sciences plans to submit IND for phase 1 trial of intranasal foralumab in Alzheimer's disease patients by Q3 2023

Proactive Investors • 10/12/22

Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

GlobeNewsWire • 10/12/22

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

GlobeNewsWire • 09/29/22

Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy

Proactive Investors • 09/28/22

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

GlobeNewsWire • 09/28/22

Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatment

Proactive Investors • 09/20/22

Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

GlobeNewsWire • 09/20/22

Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALS

Proactive Investors • 09/15/22

Tiziana Life Sciences Announces Grant received by the Brigham and Women's Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis

GlobeNewsWire • 09/15/22

Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International Conference

Proactive Investors • 08/01/22

Tiziana Life Sciences Announces Presentation at Alzheimer's Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer's Disease

GlobeNewsWire • 08/01/22

Tiziana Life Sciences appoints Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately

Proactive Investors • 07/18/22

Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

GlobeNewsWire • 07/18/22

Tiziana Life Sciences Announces Resignation of CEO

GlobeNewsWire • 07/15/22

Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient

GlobeNewsWire • 06/09/22

Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient

GlobeNewsWire • 06/09/22

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

GlobeNewsWire • 06/09/22

Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient

Benzinga • 06/08/22

Tiziana Life Sciences reports positive results from second patient in multiple sclerosis study of foralumab

Proactive Investors • 06/08/22

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

GlobeNewsWire • 06/08/22

Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs

GlobeNewsWire • 06/06/22